(redirected from D-penicillamine)
Also found in: Thesaurus, Medical, Acronyms, Encyclopedia.
Related to D-penicillamine: Cuprimine


A chelating agent, C5H11NO2S, that is a degradation product of penicillin and is used in the treatment of Wilson disease, refractory rheumatoid arthritis, and excess urinary excretion of cystine.


(Pharmacology) pharmacol a metabolite of penicillin, being a pyridoxine inhibitor and chelating agent, usually used as an anti-inflammatory in the treatment of arthritis


(ˌpɛn əˈsɪl əˌmin, -mɪn)

a chelating agent produced by the degradation of penicillin, used esp. to treat rheumatoid arthritis and lead poisoning.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.penicillamine - a drug (trade name Cuprimine) used to treat heavy metal poisoning and Wilson's disease and severe arthritis
medicament, medication, medicinal drug, medicine - (medicine) something that treats or prevents or alleviates the symptoms of disease
Mentioned in ?
References in periodicals archive ?
sup][3] As D-penicillamine performed as a copper chelater, which indirectly inhibited the activity of lysyl oxidase, abnormal elastic fibers were formed and accumulated.
Thiol derivatives, such as tiopronin and D-penicillamine, cleave cystine into two cysteine moieties and combine with cysteine to form a highly soluble disulfide compound, decreasing the excretion of poorly solublefree cystine and increasing its solubility.
Since 1955, d-penicillamine has been the most commonly used chelating agent9.
D-penicillamine (initial dose 10 mg/kg/day, maintenance dose 20 mg/kg/day, maximum dose 1 000-1 500 mg/day) and zinc (75 mg/day) treatment was given to all patients.
Ciprofloxacin (Java pharmaceutical, Pakistan), D-mannitol, D-penicillamine, Octanol, Stannous chloride, Gentistic acid (Sigma Aldrich, USA), Sodium pyrophosphate, Ascorbic acid, Acetone (Riedel, Germany), Saline (Otsuka, Pakistan), Tricholoacetic acid (Fisher Scientific, UK).
Copper chelation by D-penicillamine generates reactive oxygen species that are cytotoxic to human leukemia and breast cancer cells.
In 2002, Kaya et al reported a case in which D-penicillamine at 600 mg/day produced a modest clinical benefit and relieved symptoms for a period of time.
Method: A 24-hour urine test during a short noninvasive provocation using oral d-penicillamine [Cupramine[TM], D-Pen[TM] dimethylcysteine, mercaptovaline] or Acetyl-penicillamine, prescribed by a physician.
She began a course of copper chelation with D-penicillamine, and she awaits liver transplantation.